A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Effect of VIA-2291, a 5-Lipoxygenase Inhibitor, on Vascular Inflammation in Patients after an Acute Coronary Syndrome.
ATHEROSCLEROSIS（2015）
Key words
Arachidonate 5-lipoxygenase inhibitor,Acute coronary syndrome,18Fluorodeoxyglucose positron emission tomography,Inflammation
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined